New Oral Anticoagulants for Patients with Nonvalvular Atrial Fibrillation

Amber Holden, Nassir Azimi, Christopher Forest

Research output: Contribution to journalArticlepeer-review

Abstract

Four new oral anticoagulants have been approved for reducing stroke risk in patients with nonvalvular atrial fibrillation. Compared with warfarin, these agents offer a more predictable dose response with fewer food and drug interactions and no regular blood monitoring, although some of the drugs have an increased risk of major gastrointestinal bleeding. This article reviews the new drugs.
Original languageAmerican English
JournalJournal of the American Academy of Physician Assistants
DOIs
StatePublished - Nov 2015

Keywords

  • anticoagulation
  • nonvalvular atrial fibrillation
  • rivaroxaban
  • dabigatran
  • edoxaban
  • apixaban

Disciplines

  • Medicine and Health Sciences

Cite this